62nd ASH Annual Meeting and Exposition: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Chimeric Antigen Receptor T Cell Therapy

Oral and Poster Abstracts
Oral

Adult, ALL, Biological, CRS, Leukemia, survivorship, Diseases, neurotoxicity, CAR-Ts, Therapies, Adverse Events, Pediatric, Technology and Procedures, immunotherapy, gene editing, Lymphoid Malignancies, Study Population, Clinically relevant, Quality Improvement

Moderators:

Noelle V. Frey, MD, MS, Hospital of the University of Pennsylvania, Hospital of the University of Pennsylvania, Hospital of the University of Pennsylvania and Nitin Jain, MD, The University of Texas MD Anderson Cancer Center

Disclosures:

Frey: Kite Pharma: Consultancy, Honoraria; Syntax: Consultancy, Honoraria; Amgen: Consultancy, Honoraria. Jain: Servier: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Cellectis: Research Funding; Verastem: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Incyte: Research Funding; ADC Therapeutics: Research Funding; Precision Bioscienes: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Fate Therapeutics: Research Funding; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Research Funding; BMS: Research Funding; AstraZeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genentech: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Aprea Therapeutics: Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; TG Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; BeiGene: Honoraria, Membership on an entity's Board of Directors or advisory committees.

12:00 PM

159

Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Junfang Yang^1,2^*, Pengfei Jiang³^*, Xian Zhang, MD^1,2, Jingjing Li^1,2^*, Yan Wu²^*, Li Xu²^*, Yunchao Su²^*, Xiaona Hu²^*, Xiaoyan Zhao²^*, Qi Dong³^*, Songbai Cai³^*, Zhenguang Wang³^*, Yuezhang Chen⁴^*, Xun Ye³^*, Jiaping He³^*, Nanjing Lin³^*, Wei Cao³^*, Martina Sersch, MD, PhD³^* and Peihua Lu, MD^1,2

¹Beijing Lu Daopei Institute of Hematology, Beijing, China
²Hebei Yanda Lu Daopei Hospital, Langfang, China
³Gracell Biotech Co., Ltd, Shanghai, China
⁴Gracell Biotechnologies Ltd., Shanghai, China

12:15 PM

160

ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

Claire Roddie, PhD, MD¹^*, Maeve A O'Reilly, MBBCHBAO², Maria A V Marzolini³^*, Leigh Wood, BA⁴^*, Juliana Dias⁵^*, Amaia Cadinanos Garai, BSc MSc⁵^*, Leticia Bosshard³^*, Mahnaz Abbasian³^*, Mark W. Lowdell, BSc, MSc, PhD, FRCPath⁶^*, Graham Wheeler⁷^*, Joanna Olejnik⁸^*, Bilyana Popova, MSc⁹^*, Laura Clifton-Hadley, PhD, BSc¹⁰^*, Yashma Pathak¹¹^*, Victoria Spanswick³^*, Helen Lowe¹¹^*, John A. Hartley, PhD³^*, Farhatullah Syed¹²^*, Waseem Qasim, MBBS, PhD¹³^*, Farzin Farzaneh, PhD¹⁴^*, David C. Linch¹²^*, Martin Pule, MD PhD³^* and Karl S Peggs, MD, PhD¹⁵^*

¹Department of Haematology, Clinical Lead, CAR-T, University College London Hospitals Senior Lecturer in Haematology, University College London NHS Foundation Trust, London, United Kingdom
²Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
³UCL Cancer Institute, London, United Kingdom
⁴University College Hospital London, london, United Kingdom
⁵Cancer Institute, University College London, London, United Kingdom
⁶Cellular Therapeutics, University College London, London, United Kingdom
⁷Cancer Research UK & UCL Cancer Trials Centre, UCL, London, United Kingdom
⁸UCL Cancer Trials Centre, London, United Kingdom
⁹CRUK UCL Cancer Trials Centre, UCL, London, United Kingdom
¹⁰Cancer Research UK and UCL Cancer Trials Centre, London, United Kingdom
¹¹UCL Cancer Institute, University College London, London, United Kingdom
¹²University College London, London, United Kingdom
¹³Institute of Child Health, UCL, London, ENG, United Kingdom
¹⁴King's College London, London, United Kingdom
¹⁵University College London Cancer Institute, UCL Cancer Institute, London, United Kingdom

12:30 PM

161

Feasibility, and Efficacy of Donor-Derived cd19-Targeted Car t-Cell Therapy in Refractory/Relapsed(r/r)b-Cell Acute Lymphoblastic Leukemia (b-all) Patients

Xian Zhang, MD¹, Junfang Yang²^*, Wenqian Li³^*, Gailing Zhang, MD.³^*, Yunchao Su³^*, Yanze Shi³^*, Dan Song³^*, Min Zhang³^*, Jiujiang He³^*, Li Xu³^*, Liyuan Qiu⁴^*, Xin-An Lu⁴^*, Fei Wu⁴^*, Jianqiang Li, PhD⁴, Dandan Chen⁴^*, Xiangqun Li⁴^*, Ziyu Li⁴^*, Jingjing Li⁴^* and Peihua Lu, MD²

¹Beijing Lu Daopei Institute of Hematology, Beijing, China
²Hebei Yanda Lu Daopei Hospital, Langfang, China
³Hebei Yanda Lu Daopei Hospital, beijing, China
⁴Hebei Yanda Lu Daopei Hospital, langfang, China

12:45 PM

162

CAR2.0 Therapy for the Management of Post-Transplantation Relapse of B-Cell Acute Lymphoblastic Leukemia

Rui Zhang, MSc¹^*, Juan Xiao, MD, PhD²^*, Zhouyang Liu, MSc²^*, Yuan Sun, MD²^*, Sanfang Tu, MD & PhD³^*, Yuhua Li, MD & PhD³, Leping Zhang, MD, PhD⁴^*, Yifei Cheng, MD, PhD⁵^*, Song Xue, MSc⁶^*, Yongping Zhang, MD, PhD⁶^*, Kai Wang, MD, PhD⁷, Bin Wang, MD, MSc⁷^*, Huyong Zheng, MD, PhD⁷, Nobuhiro Nishio, MD, PhD⁸^*, Yoshiyuki Takahashi, MD, PhD⁸^*, Jia Feng, MD, PhD⁹^*, Haichan Xu, MD, PhD⁹^*, Yuchen Liu, MSc¹^*, Yuchen Li, MSc¹^*, Cheng Jiao, MD, PhD¹^*, Biljana N. Horn, MD¹⁰ and Lung-Ji Chang, PhD^1,7,8,11

¹Geno-Immune Medical Institute, Shenzhen, China
²Department of Hematology, Beijing Jingdu Children's Hospital, Beijing, China
³Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China
⁴Department of Hematology, Peking University People's Hospital, Beijing, China
⁵Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China
⁶Department of Hematology, Aerospace Central Hospital, Beijing, China
⁷Department of Hematology, Beijing Children's Hospital, Beijing, China
⁸Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
⁹Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China
¹⁰UF Shand's Children Hospital, University of Florida, Gainesville, FL
¹¹Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL

1:00 PM

163

Preliminary Results of Balli-01: A Phase I Study of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor) in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Nitin Jain, MD¹, Gail J. Roboz, MD², Marina Konopleva, MD, PhD³, Hongtao Liu, MD, PhD⁴, Elias Jabbour, MD¹, Camille Poirot, Pharm.D.⁵^*, Cécile Schiffer-Manniou, PhD⁵^*, Agnès Gouble, PhD⁵^*, Asifa Haider, PhD⁵^*, Oleg Zernovak, MD⁵^* and Richard A. Larson, MD⁶

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Weill Medical College of Cornell University New York-Presbyterian Hospital, New York, NY
³Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX
⁴Department of Medicine, Section of Hematology-Oncology, University of Chicago, Chicago, IL
⁵Cellectis, Paris, France
⁶Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL

1:15 PM

164

A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study

Erica Brivio, MD^1,2^*, Franco Locatelli, MD³^*, Adriana Thano^1,4^*, Arnaud Petit, MD, PhD⁵^*, Britta Julia Vormoor, MD⁶^*, Susana Rives⁷^*, Bella Bielorai, MD⁸^*, Claudia Rossig⁹, Carmelo Rizzari¹⁰^*, Vincent H.J. Van Der Velden, PhD¹¹^*, Anneke C.J. Ammerlaan¹^*, Monique L. Den Boer, PhD^1,2,12, Barbara Sleight, MD¹³^*, Gernot Engstler¹⁴^*, Jan Stary, MD, PhD¹⁵^*, Francisco José Bautista Sirvent, MD, PhD¹⁶^*, Christiane Chen-Santel^17,18^*, Bénédicte Bruno, MD¹⁹^*, Yves Bertrand, M.D.²⁰^*, Fanny Rialland, MD²¹^*, Geneviève Plat²²^*, Dirk Reinhardt, MD²³, Luciana Vinti, MD²⁴^*, Arend von Stackelberg, MD²⁵ and Christian Michel Zwaan^1,2^*

¹Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
²Department of Pediatric Oncology/Hematology, Erasmus University Medical Center-Sophia Children’s Hospital, Rotterdam, Netherlands
³Pediatric Hemato-Oncology, IRCCS, Bambino Gesù Children’s Hospital, Sapienza, Univ of Rome, Rome, Italy
⁴Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, NLD
⁵department of pediatric Hematology and Oncology, Hopital Armand Trousseau, APHP, Sorbonne Université, Paris, France
⁶Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, Netherlands
⁷Pediatric Oncology and Hematology Department, Hospital Sant Joan de Déu de Barcelona, Barcelona, ESP
⁸Division of Pediatric Hematology and Oncology, Sheba Medical Center, Ramat-Gan, ISR
⁹Pediatric Hematology and Oncology, University Children's Hospital Muenster, Münster, Germany
¹⁰Pediatric Hematology-Oncology Unit, MBBM Foundation, ASST Monza, University of Milano-Bicocca, Monza, Italy
¹¹Department of Immunology, Erasmus University Medical Center, Rotterdam, NLD
¹²Oncode Institute, Utrecht, Netherlands
¹³Pfizer Inc, Groton, CT
¹⁴St Anna Children's Hospital, Medical University of Vienna, Vienna, Austria
¹⁵Department of Pediatric Hematology and Oncology, University Hospital Motol, Prague, Czech Republic
¹⁶Pediatric Oncology and hematology Department, Hospital Niño Jesus, Madrid, Spain
¹⁷Department of Pediatrics, Division of Oncology and Hematology, Charité – Universitätsmedizin Berlin, Berlin, Germany
¹⁸Department of Pediatrics, University Medical Centre, Rostock, Rostock, Germany
¹⁹Pediatric Hematology, Hôpital Jeanne de Flandre, CHRU de Lille, Lille, France
²⁰Institute of Pediatric Hematology and Oncology, Civil Hospital of Lyon, Claude Bernard University, Lyon, France
²¹Service Onco-Hématologie Pédiatrique, Hôpital Mère-Enfant, Nantes University Hospital, Nantes, France
²²Service d’Hématologie-Immunologie-Oncologie, Hôpital des Enfants, CHU Toulouse, Toulouse, France
²³Department of Pediatric Hematology and Oncology, Essen University Hospital, Essen, Germany
²⁴Department of Hematology/Oncology and of Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesù, Sapienza, University of Rome, Rome, Italy
²⁵IntReALL study group, Berlin, Germany

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

614.O1.6 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Chimeric Antigen Receptor T Cell Therapy